[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343980-105":59,"doc-detail-343980-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","treatment-sequencing-and-independent-outcomes-of-first-and-second-line-chemotherapy-in-a-retrospective-series-of-patients-with-biliary-tract-cancer","Treatment Sequencing and Independent Outcomes of First-and Second-Line Chemotherapy in a Retrospective Series of Patients with Biliary Tract Cancer","","Biliary tract cancers (BTCs) are aggressive malignancies with limited treatment options and scarce prospective evidence on how sequencing affects survival. A retrospective, real-world cohort from a single Italian referral hospital analyzed 60 patients with locally advanced or metastatic BTC who received at least three lines of chemotherapy; 56 were included. Outcomes were compared between a “standard” pre-immunotherapy sequence (Gemcitabine/Cisplatin then mFOLFOX) and other regimens, with additional comparisons within first- and second-line settings.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/treatment-sequencing-and-independent-outcomes-of-first-and-second-line-chemotherapy-in-a-retrospective-series-of-patients-with-biliary-tract-cancer/343980/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/treatment-sequencing-and-independent-outcomes-of-first-and-second-line-chemotherapy-in-a-retrospective-series-of-patients-with-biliary-tract-cancer/343980.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main objective of the retrospective study on BTC patients?","Question",{"text":113,"@type":114},"To evaluate how treatment sequencing influences survival in advanced biliary tract cancer patients treated in real-world practice before immunotherapy approval.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were first-line and second-line chemotherapy regimens compared in the analysis?",{"text":118,"@type":114},"First-line outcomes compared GemCis versus other doublets (mainly Gemcitabine/Oxaliplatin), while second-line outcomes compared mFOLFOX versus other regimens (including chemotherapy doublets).",{"name":120,"@type":111,"acceptedAnswer":121},"Did the study find significant survival differences between the standard sequence and other combinations?",{"text":122,"@type":114},"No significant survival differences were observed between the standard pre-immunotherapy sequence group and the control group, though patient selection focused on those receiving at least three chemotherapy lines.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},343980,1790174445,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Brief Report  \nTreatment Sequencing and Independent Outcomes of First-and Second-Line Chemotherapy in a Retrospective Series of Patients with Biliary Tract Cancer  \nGiorgio Frega 1, Andrea Palloni 2, Chiara Deiana 2, Alessandro Rizzo 3, Angela Dalia Ricci 4 and Giovanni Brandi 2, *  \nCitation: Frega, G.; Palloni, A.; Deiana, C.; Rizzo, A.; Ricci, A.D.; Brandi, G. Treatment Sequencing and Independent Outcomes of First-and Second-Line Chemotherapy in a Retrospective Series of Patients with Biliary Tract Cancer. J. Clin. Med. 2024, 13, 7262. [https://doi.org/10.3390/](https://doi.org/10.3390/)  \njcm13237262  \nAcademic Editor: Manuel Diez-Alonso  \nReceived: 18 October 2024  \nRevised: 25 November 2024  \nAccepted: 27 November 2024  \nPublished: 29 November 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Osteoncology, Soft Tissue and Bone Sarcomas, Innovative Therapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; [giorgio.frega@ior.it](giorgio.frega@ior.it)  \n2 Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; [andrea.palloni@aosp.bo.it](andrea.palloni@aosp.bo.it) (A.P.); [chiarad.kw@gmail.com](chiarad.kw@gmail.com) (C.D.)  \n3 Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, IRCCS Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65,  \n70124 Bari, Italy; [rizzo.alessandro179@gmail.com](rizzo.alessandro179@gmail.com)  \n4 Medical Oncology Unit, National Institute of Gastroenterology,“Saverio de Bellis” Research Hospital, 70013 Castellana Grotte, Italy; [dalia.ricci@gmail.com](dalia.ricci@gmail.com)  \n* Correspondence: [giovanni.brandi@unibo.it](giovanni.brandi@unibo.it)  \nAbstract: Background/Objectives: Biliary tract cancers (BTCs) are aggressive neoplasms with limited therapeutic options. The amount of prospective evidence is poor, and limited data are available on the impact of treatment sequencing on survival. Here we report a real-world experience of patients with advanced BTC treated with at least three lines of therapy. We evaluated the impact of sequential treatments, and we further compared the efficacy of Gemcitabine/Cisplatin (GemCis) and mFOLFOX to other first-and second-line chemotherapy regimens, respectively. Methods: Data on 60 patients with locally advanced or metastatic BTC under the care of a single Italian referral hospital and treated with at least three lines of chemotherapy were retrospectively collected. Data from 56 patients were included in the analysis. Survival analyses were performed using R software (v1.2.5042) . Results: We compared the outcomes of patients treated according to the “standard” pre-immunotherapy sequence (GemCis and mFOLFOX in the first and second lines, respectively) versus those treated with all other combinations (“control” group) . Our analysis did not show significant survival differences between the two groups. However, it should be noted that we selected long-survival patients by including only those who received at least three or more lines of chemotherapy. Focusing on the first-line setting, no significant differences in both mPFS and mOS emerged by comparing GemCis versus other doublets (mainly Gemcitabine/Oxaliplatin) . Similarly, mPFS and mOS from second-line treatment did not statistically differ between patients treated with mFOLFOX versus those treated with other regimens (71% chemotherapy doublets) . Conclusions: Our series provides real-world outcomes of patients with advanced BTC before the approval of immunotherapy. Even considering the monocentric and retrospective design, our study represents one of the first anal","cbCairJx5Nsw9tKM","https://ap.wps.com/l/cbCairJx5Nsw9tKM","pdf",1226390,"English","# Abstract\n# Introduction","[{\"question\":\"What was the main objective of the retrospective study on BTC patients?\",\"answer\":\"To evaluate how treatment sequencing influences survival in advanced biliary tract cancer patients treated in real-world practice before immunotherapy approval.\"},{\"question\":\"How were first-line and second-line chemotherapy regimens compared in the analysis?\",\"answer\":\"First-line outcomes compared GemCis versus other doublets (mainly Gemcitabine/Oxaliplatin), while second-line outcomes compared mFOLFOX versus other regimens (including chemotherapy doublets).\"},{\"question\":\"Did the study find significant survival differences between the standard sequence and other combinations?\",\"answer\":\"No significant survival differences were observed between the standard pre-immunotherapy sequence group and the control group, though patient selection focused on those receiving at least three chemotherapy lines.\"}]","Treatment Sequencing and Independent Outcomes of First-and Second-Line Chemotherapy in a Retrospective Series of Patients with Biliary Tract Cancer | PDF",1790052673,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10634580cdc11cda81f23bb854315985.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e792abc580112764943c0fee42a704f.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/814647cb9848eb04a9e8c686da820d7c.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/892a66ec9906153314fb27c452d88c7b.webp",980,1385]